Chromosomal rearrangements have a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions 1 . A recently discovered example is a fusion between the genes echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK), generated by an inversion on the short arm of chromosome 2: inv(2) (p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) 2 and is clinically relevant because it confers sensitivity to ALK inhibitors 3 . Despite their importance, modelling such genetic events in mice has proven challenging and requires complex manipulation of the germ line. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumours invariably harbour the Eml4-Alk inversion, express the Eml4-Alk fusion gene, display histopathological and molecular features typical of ALK 1 human NSCLCs, and respond to treatment with ALK inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
Genetically engineered mouse models of human cancers have proven indispensable to dissect the molecular mechanisms underlying tumorigenesis 4 and provide powerful preclinical platforms for studying drug sensitivity 5 and resistance [6] [7] [8] . Although many gain-and loss-of-function mutations observed in human cancers can be modelled using current gene-targeting technologies, chromosomal rearrangements leading to oncogenic gene fusions have proven challenging to faithfully recapitulate Eml4-Alk Alk-Eml4
In ( (17) involving the Eml4 and Alk loci. Red arrows indicate the sites recognized by the sgRNAs. b, A schematic of the loci before and after the inversion with the location of the primers used (top panel). PCRs were performed on genomic DNA extracted from NIH/3T3 cells transfected with the indicated pX330 constructs (middle panels). The PCR bands were sub-cloned and the sequences of four independent clones and a representative chromatogram are shown in the lower panels. c, Schematic of the Eml4-Alk fusion transcript (top panel). Detection of the Eml4-Alk fusion transcript by RT-PCR on total RNAs extracted from NIH/3T3 cells transfected with the indicated pX330 constructs (bottom left panel). Sequence of the PCR product showing the correct Eml4-Alk junction (bottom right panel). d, Schematic of the break-apart interphase FISH strategy. In cells with the Eml4-Alk inversion, the red and green probes become separated, and the green and orange probes become juxtaposed. e, Break-apart interphase FISH assay on a NIH/3T3 clone selected from cells co-transfected with pX330-Eml4 and pX330-Alk. Both wild type (white arrows) and the In(17) Eml4-Alk allele (red arrow) are detected. in mice. Ectopic expression of fusion oncoproteins from transgenes is widely used to study their oncogenic properties [9] [10] [11] [12] [13] , though with this approach the fusion protein is invariably expressed at non-physiologic levels and neither the role of reduced dosage of the wild-type alleles nor the contribution of the reciprocal product of the translocation can be examined. Strategies that express the fusion transcript from the endogenous locus of the 59 element 14 only partially address these limitations, whereas approaches that engineer loxP sites at each breakpoint and produce rearrangements in the presence of Cre recombinase 15, 16 are laborious and have limited applications. Novel genome-editing technologies provide a potentially more flexible strategy to produce precise genomic changes including oncogenic chromosomal rearrangements [17] [18] [19] [20] , but they have not yet been adapted to model such rearrangements in vivo.
In the mouse genome, Eml4 and Alk are located on chromosome 17, approximately 11 megabases (Mb) apart, in a region that is syntenic to human chromosome 2(p21-p23) ( Fig. 1a) . We attempted to model the most common EML4-ALK variant in human NSCLCs 21 by introducing concomitant double-strand DNA breaks at intron 14 of Eml4 (which corresponds to intron 13 of EML4) and at intron 19 of Alk (Fig. 1a, b and Extended Data Fig. 1 ). To induce the DNA breaks we chose the CRISPR system 22 because it only requires co-expression of Cas9 and an appropriately designed single-guide RNA molecule (sgRNA) 23 .
We cloned sgRNAs targeting the Eml4 and Alk sites into the Cas9expressing plasmid pX330 (ref. 24 ) and co-transfected the resulting constructs in NIH/3T3. PCR analysis demonstrated the induction of the Eml4-Alk inversion and of a large deletion of the region between the two cut sites in the transfected cell population (Fig. 1b) . The presence of the desired Eml4-Alk inversion was confirmed by sequencing the corresponding Eml4-Alk fusion transcript ( Fig. 1c ) and directly visualized by interphase FISH (Fig. 1d, e ). Using a similar strategy, we also modelled the Npm1-Alk rearrangement, a reciprocal chromosomal translocation commonly observed in anaplastic large cell lymphomas 25 (Extended Data Fig. 2 ). These results confirm that the CRISPR system can be adapted to engineer large deletions, inversions, and chromosomal translocations in eukaryotic cells.
Although appropriate for cell-based experiments, expression of two sgRNAs from separate constructs would be impractical in vivo. We therefore engineered plasmids to simultaneously express Cas9 and two distinct sgRNAs from tandem U6 promoters (Extended Data Fig. 3a 
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sgRNAs, efficient cleavage of the targeted sites, and accumulation of the Eml4-Alk inversion (Extended Data Fig. 3b-d ).
To deliver Cas9 and sgRNAs targeting the Alk and Eml4 loci to the lungs of adult mice, we next transferred the dual sgRNA/Cas9 cassette into an adenoviral shuttle vector (Extended Data Fig. 4a ) and produced recombinant adenoviruses (hereafter referred to as 'Ad-EA'). Adenoviruses are ideal because they efficiently infect the lung epithelium of adult mice 26 and do not integrate into the host genome. Infection of mouse embryo fibroblasts (MEFs) with Ad-EA led to the expression of Cas9 and both sgRNAs, and to the rapid generation of the desired Eml4-Alk inversion (Extended Data Fig. 4b-d ). We estimated that the Eml4-Alk inversion was produced in approximately 3-4% of infected MEFs (Extended Data Fig. 4e, f) .
To induce the Eml4-Alk rearrangement in vivo we next infected a cohort of adult CD1 and C57BL/6J (B6) mice by intratracheal instillation of Ad-EA (n 5 52: 22 B6, 30 CD1) or control adenoviruses expressing either the Cre recombinase (Ad-Cre, n 5 15: 6 B6, 9 CD1) or Cas9 alone (Ad-Cas9, Fig. 2a -c, n 5 19: 9 B6, 10 CD1). An annotated list of all infected animals is provided in Extended Data Table 1 .
At two days, and at one week post-infection, the lungs appeared histologically normal with no obvious signs of cytoxicity except for the presence of occasional inflammatory infiltrates ( Fig. 2a and data not shown). However, one month after Ad-EA infection, the lungs of mice of both strains presented multiple small lesions that upon histopathological examination appeared to be papillary intrabronchiolar epithelial hyperplasia, atypical adenomatous hyperplasia (AAH) or early welldifferentiated adenocarcinomas. By 6-8 weeks post-infection, larger tumours were easily detectable by micro-computed tomography (mCT) and macroscopically visible at necropsy ( Fig. 2b) . At 12-14 weeks postinfection, the lungs of Ad-EA-infected mice invariably contained multiple large lesions histologically classified as lung adenocarcinomas.
In Ad-EA-infected animals, multiple bilateral lung tumours were frequently detected by 4-7 weeks post-infection (n 5 23/26 mice), and invariably after 8 weeks post-infection (n 5 34). In contrast, Ad-Cre-infected mice remained tumour-free at all time points examined (n 5 14 mice, range 4-18 weeks), with the exception of two CD1 mice in each of which we observed a single small adenoma. Analogously, even at the latest time point examined (9 weeks post-infection), none of the Ad-Cas9 infected The full-length PCR products were sequenced on both strands. A chromatogram of the Eml4-Alk junction is shown (right). f, Representative immunohistochemistry of Ad-EA-induced lung tumours stained with antibodies against the indicated phospho-proteins. A bar-plot of staining intensity for the indicated phospho-proteins is also shown. Tumours from two mice for each group were scored.
LETTER RESEARCH
mice presented lung tumours (n 5 8 mice), whereas at same time point all Ad-EA infected mice had developed multiple tumours (P , 0.0001, Fisher's exact test). These results indicate that intratracheal delivery of Ad-EA can initiate lung tumorigenesis with high penetrance and low latency, and that this effect cannot be attributed to adenoviral infection or Cas9 expression alone.
All tumours examined were positive for the pneumocyte marker Nkx2-1 (also known as TTF1) and negative for p63 and Sox2, in agreement with the diagnosis of lung adenocarcinoma (Fig. 2c) . The tumours were also strongly positive for the alveolar type II marker surfactant protein C (SpC), whereas the Clara cell marker CCSP (also known as CC10) was undetectable. The adenocarcinomas had a papillary or, less frequently, acinar architecture (Fig. 2d, e ). Most of these tumours were in close proximity to bronchi and bronchioles showing papillary epithelial hyperplasia (Fig. 2a, f) , and areas of AAH were frequently observed, especially at earlier time points (Fig. 2g ). The majority of tumour cells appeared low-grade, with occasional instances of intermediate nuclear atypia with enlarged nuclei and prominent nucleoli (Fig. 2h, top and bottom images). Approximately 20% of tumours contained cells with a large cytoplasmic vacuole and a peripherally located nucleus (Fig. 2i , top and bottom images). These cells are reminiscent of signet ring cells, which are commonly observed in human ALK 1 NSCLC 27 . Approximately 30% of adenocarcinomas displayed areas of intense positivity at the periodic acid-Schiff (PAS) staining (Fig. 2j, top 
and bottom images).
Interphase FISH analysis demonstrated the presence of a mono-or bi-allelic Eml4-Alk inversion in every Ad-EA-induced tumour examined (n 5 4 animals) ( Fig. 3a) , but not in control K-Ras G12D -driven tumours 28 (Fig. 3b ). We further confirmed the presence of the Eml4-Alk rearrangement and expression of the full-length Eml4-Alk transcript in microdissected tumours by performing genomic PCR and reverse transcription PCR followed by sequencing ( Fig. 3c-e ).
Activation of the human ALK oncogene via deregulation, translocation, or amplification has been shown to lead to constitutive phosphorylation of ERK, STAT3, and AKT 29 . At 12-14 weeks post-infection, all lung tumours derived from Ad-EA-injected mice showed phosphorylation and nuclear localization of Stat3. Phosphorylation of Akt and Erk1/2 were also frequently, but not invariably, observed (Fig. 3f ).
Finally, we examined the sensitivity of Ad-EA-induced lung tumours to crizotinib, a dual ALK/MET inhibitor used in the clinic to treat patients affected by ALK 1 NSCLCs 3 . Ten Ad-EA-infected CD1 mice were monitored by mCT scans starting at 9 weeks post-infection until the appearance of multiple large lung tumours, at which point the animals were randomly assigned to receive a daily dose of crizotinib (n 5 7) or vehicle (n 5 3) (Fig. 4a ). After two weeks of treatment the animals in the crizotinib group displayed complete (6/7) or partial (1/7) tumour regression, as indicated by mCT scans and confirmed at necropsy, whereas all control animals showed signs of disease progression (Fig. 4b, c , Extended Data Fig. 5 , Extended Data Table 2 and Supplementary Videos 1-10). Histological analysis showed that in the crizotinib group the tumours had undergone marked atrophy or were replaced by areas of intense inflammatory necrosis (Fig. 4d, e ).
Collectively, these results demonstrate that the CRISPR technology can be adapted to engineer oncogenic chromosomal rearrangements in mice. The new mouse model of Eml4-Alk-driven lung cancer we have generated to validate this approach faithfully recapitulates the molecular and biological properties of human ALK 1 NSCLCS, including a marked sensitivity to the ALK-inhibitor crizotinib. This model provides unique opportunities to dissect the molecular mechanisms through which Eml-Alk drives tumour formation, to test the efficacy of targeted therapies, and to investigate the mechanisms of drug resistance in vivo.
The CRISPR-based strategy described here offers several advantages over germline engineering via transgenesis or homologous recombination. 
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By inducing the rearrangement in only a subset of somatic cells, the resulting lesions more closely recapitulate the stochastic nature of tumour formation in humans. In addition, by modifying the endogenous loci, expression of the resulting fusion genes is subjected to physiologic transcriptional and post-transcriptional regulation, accurately modelling the reduced dosage of the wild-type alleles and the expression of the reciprocal product of the translocation/inversion. Finally, because our method requires only the generation of an appropriate viral vector and no germline manipulations, it can be readily adapted to model chromosomal rearrangements in other species, including non-human primates, and as such will facilitate the study of species-specific differences in tumour progression and therapy response in vivo.
Despite these key advantages, some caveats of the CRISPR technology must also be considered. The efficiency with which the rearrangements are induced is relatively low and is likely to be affected by the distance between the cut sites and their accessibility to Cas9. Although a low efficiency may be desirable when inducing oncogenic rearrangements, it is a concern if the goal is to generate chromosomal rearrangements in the majority of cells. Furthermore, every possible allele combination of the two target loci (indels, inversions, deletions) will be induced by the dual sgRNA/Cas9 system 30 , potentially complicating the interpretation of these studies.
In summary, the general strategy we have developed substantially expands our ability to model cancers driven by chromosomal rearrangements and will facilitate the development of pre-clinical models to study the mechanisms of drug resistance and test novel therapies.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Plasmids and adenoviral vectors. The pX330 vector expressing Cas9 (Addgene plasmid 42230) was digested with BbsI and ligated to annealed and phosphorylated sgRNA oligonucleotides targeting Eml4, Alk and Npm1. For cloning of tandem U6-sgRNA-Cas9 constructs, the second U6-sgRNA cassette was amplified using primers containing the XbaI and KpnI sites and cloned into the pX330 construct containing the appropriate sgRNA. For Adeno-Eml4-Alk cloning, pX330-Alk-Eml4 vector was modified by adding an XhoI site upstream the first U6 promoter. An EcoRI/XhoI fragment containing the double U6-sgRNA cassette and the Flag-tagged Cas9 was then ligated into the EcoRI/XhoI-digested pacAd5 shuttle vector. NIH/3T3 cells were transfected in 6-well plates with 3 mg of total plasmid DNA per well using lipofectamine 2000 (Invitrogen) following the manufacturer's instructions. To enrich for transfected cells, transfections included 1 mg of a plasmid expressing the Puroresistance gene (pSico) and cells were incubated with 2 mg ml 21 puromycin for 2 days. Recombinant adenoviruses were generated by Viraquest (Ad-EA and Ad-Cas9) or purchased from the University of Iowa (Ad-Cre). MEFs infections were performed by adding adenovirus (3 3 10 6 plaque-forming units (p.f.u.)) to each well of a 6-well plate. PCR and RT-PCR analysis. For PCR analysis of genomic DNA, cells were collected in lysis buffer (100 nM Tris-HCl pH 8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl supplemented with fresh proteinase K at final concentration of 100 ng ml 21 ). Genomic DNA was extracted with phenol-chloroform-isoamylic alcohol and precipitated in ethanol. The DNA pellet was dried and resuspended in double-distilled water. For RT-PCR, total RNAs were extracted with TRIzol (Life Technologies) following manufacturer's instructions. cDNAs were prepared using the Superscript III kit, following the manufacturer's instructions. The primers and the primer pairs used in the various PCR reactions are provided in Extended Data Tables 3 and 4 . Quantification of inversion efficiency in MEFs. We first isolated an NIH/3T3 subclone carrying a mono-allelic Eml4-Alk inversion validated by interphase FISH. Genomic DNA extracted from this clone was mixed with increasing amounts of genomic DNA from parental NIH/3T3 cells to generate a series of standards containing known percentage of Eml4-Alk alleles. The standards and the test samples were then subjected to quantitative PCR (Applied Biosystem) using primers amplifying the Eml4-Alk junction (Eml4-for and Alk-rev, see Extended Data Table 3 ) or a control gene (miR-17-92-gDNA-for and miR-17-92-gDNA-rev) and the fraction of Eml4-Alk alleles in the test was calculated by plotting the DDC t values on the standard curve. qPCR analysis was performed using SYBR Green (Life Technology). Cell lines. MEFs were generated from E14.5 wild-type embryos following standard procedures. NIH/3T3 were purchased from ATCC. Mouse husbandry and adenoviral infection. Mice were purchased from The Jackson Laboratory (C57BL/6J) or from Charles River (CD1) and housed in the SPF MSKCC animal facility, where the health status of the colony is constantly monitored by the veterinary staff and by a sentinel program. For adenoviral infection, 6-10-week-old mice were anaesthetized by intraperitoneal injection of ketamine (80 mg per kg) and xylazine (10 mg per kg) and treated by intratracheal instillation of 1.5 3 10 8 p.f.u. adenovirus per mouse, as previously described 26 . Investigators were not blinded with respect to which adenovirus was injected. All studies and procedures were approved by the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee. Interphase fluorescent in situ hybridization. Interphase FISH experiments were performed and interpreted by the MSKCC cytogenetic core using a 3-colour probe mix designed to detect and discriminate between Alk-Eml4 fusion and other rearrangements of Alk. The probe mix comprised mouse BAC clones mapping to: 39 Alk (17qE1.3, RP23-306H20, RP23-397M18 labelled with green dUTP), 59 Alk (17qE1.3, RP23-12H17, RP23-403F20 labelled with red dUTP), and 59 Eml4 (17qE4, RP23-193B15 labelled with orange dUTP). Probe labelling, hybridization, washing, and fluorescence detection were done according to standard procedures. Cell line collection and metaphase spreads were prepared according to standard cytogenetics procedures. For NIH/3T3, FISH signals were enumerated in a minimum of 20 metaphases to determine locus specificity, and 100 interphase cells to determine Alk-Eml4 fusion status. Each paraffin section was first scanned under 3100 objective to assess signal pattern and select representative regions for analysis. At least three images per representative region were captured (each image was a compressed stack of 12 z-sections at 0.5 micron intervals). Signal counts were performed on the captured images and a minimum of 50 interphase nuclei was analysed to determine the Alk-Eml4 fusion status. Based on the observed distance between the green (39 Alk), red (59 Alk), and orange (59 Eml4) signal in the negative controls (parental cell line and Ad-Cre-infected cells), interphase cells were classified as normal, Eml4-Alk positive, or other. Surveyor assay. The genomic region flanking the CRISPR/Cas9 target site was first amplified by PCR. After a cycle of melting and re-annealing to allow heteroduplex formation, the amplicon was digested with the surveyor nuclease (Transgenomic) for 1 h at 42 uC according to the manufacturer's directions and the digestion products were separated on a 2% agarose gel. Northern blot analysis. 10 mg of RNA previously extracted with TRIzol (Life Technologies) were run on a 15% denaturing polyacrylamide gel and blotted on a nitrocellulose membrane for 1 h at 100 V at room temperature. The membranes were then hybridized to radiolabelled oligonucleotides complementary to the Alk (59-TACAGATAGACATGCCAGGAC), Eml4 (59-TCCTAGTAGACCCCGACAAA C) sgRNAs, or mU6 (59-GCAGGGGCCATGCTAATCTTCTCTGTATCG) dissolved in ExpressHyb (Clontech) at 42 uC overnight. Washes were performed at room temperature in 2X SSC and 0.2 SSC. Lung processing and antibodies for immunohistochemistry. Lungs were inflated by intratracheal injection of 4% paraformaldehyde (PFA), incubated for 18-24 h in 4% PFA, and then transferred to 70% ethanol for at least 24 h before further processing. The following antibodies were used: phospho-Stat3 (Tyr705, Cell Signaling Technology #9135, 0.1 mg ml 21 ); phospho-Erk1/2 (Thr202/Tyr204, Cell Signaling Technology #4370 1 mg ml 21 ); phospho-Akt (Ser473, Cell Signaling Technology #4060 1 mg ml 21 ); Nkx2-1 (Epitomics, EP1584Y 1:1,200); Flag (Sigma, M2 1:1,000); P63 (Santa Cruz (H-137) sc8343, 1:1,000); Sox2 (Cell Signaling Technology, C70B1 #3728, 1:1,000); CC10/CCSP (Millipore, 07-623, 1:2,000); SpC (Millipore, AB3786, 1:1,000). mCT imaging. mCT Scans were performed on the Mediso Nano SPECT/CT System covering only the lung fields of each mouse. Each scan averaged approximately 5 min using 240 projections with an exposure time of 1,000 ms set at a pitch of 1 degree. The tube energy of the X-ray was 55 kVp and 145 mA. The in-plane voxel sizes chosen were small and thin creating a voxel size of 73 3 73 3 73 mm. The final reconstructed image consisted of 368 3 368 3 1,897 voxels. Scans were analysed with the Osirix software. Crizotinib treatment. Mice were randomized to receive either control vehicle (water) or crizotinib at 100 mg per kg per os daily for at least 14 consecutive days. Mice were monitored daily for weight loss and clinical signs. Investigators were not blind with respect to treatment.
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During the assembly of Fig. 1b 
